Wee wish to inform that the Board of Directors in its meeting held today approved the un-audited financial results for the quarter ended on 30.06.2026

Corporate Office: 1506, Chiranjiv Tower, Shivalik Rasayan Limited 43, Nehru Place, New Delhi-19 Tel: +91 11 47589500 (30 Lines), 26221811/26418182 E-Mail : info@shivalikrasayan.com Website: www.shivalikrasayan.com CIN: L24237UR1979PLC005041 Ref: STEX/OUTCOME/2026-27 Date: 14.08.2026 BSE Limited National Stock Exchange of India Limited Department of Corporate Services-Listing Exchange Plaza, Bandra Kurla Complex PJ Towers, Dalal Street Bandra (E) Mumbai- 400051 Mumbai- 400001 Scrip Code- 539148 Symbol- SHIVALIK Sub. : Outcome of Board Meeting Dear Sir, We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un- Audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on June 30, 2026. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following: a) Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2026 as Annexure-A and b) Unaudited Segment-wise Revenue, Results, Assets and Liabilities of the Company, both Standalone and Consolidated, for the Quarter ended June 30, 2026; as Annexure-B and c) Limited Review Report from M/s Rahul Chaudhary & Associates, Chartered Accountants on the Un- Audited Financial Results (Standalone & Consolidated) as Annexure-C Further Board of Directors at their meeting approved the following resolutions: a) Approved draft Annual Report for the financial year 2025-26. b) The 48th AGM of the Company will be held on Monday the September 28, 2026 at 1:00 pm at Hotel Saffron Leaf, GMS Road Dehradun, Uttarakhand-248146. Pursuant to rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed Monday, September 21, 2026 as the cut-off date for the purpose of determining the eligible shareholders (holding shares either in physical or dematerialised form) to cast their vote electronically from Friday, September 25, 2026 to Sunday, September 27, 2026. In compliance of SEBI (LODR), Regulations, 2015 the Board of Directors of the Company have decided to close the Register of Members and other Transfer books of the Company with a view to enable the Company to make payment of Final Dividend @10% or Rs. 0.50 per Equity Share (if decided by the members in their forthcoming AGM) for the Financial year 2025-26. The aforesaid register will remain close from Tuesday, September 22, 2026 to Monday, September 28, 2026 (both days inclusive) Regd. Office & Factory: Kolhupani, P.O. Chandanwari, Dehradun-248 007. Phone: 0135-2773429, 2772038, E-mail: ddn@shivalikrasayan.com Works Dahej-II: D-2/CH/41/A, GIDC Industrial Estates, Dahej-II, Pin- 392140 Distt, Bharuch (Gujarat) R&D Centre: SP-1192 A&B, Phase-IV, Industrial Area, Bhiwadi-301019, Dist. Alwar, Bhiwadi (Rajasthan) Tel.: 07240009670 Corporate Office: 1506, Chiranjiv Tower, Shivalik Rasayan Limited 43, Nehru Place, New Delhi-19 Tel: +91 11 47589500 (30 Lines), 26221811/26418182 E-Mail : info@shivalikrasayan.com Website: www.shivalikrasayan.com CIN: L24237UR1979PLC005041 The meeting of the Board of Directors commenced 03:45 p.m. and concluded at 5:00 p.m. The Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2026, as approved by the Board, will also be available on the Company’s website at www.shivalikrasayan.com. This is for your information and records. Thanking You. Yours faithfully, For Shivalik Rasayan Limited Parul Choudhary Company Secretary & Compliance Officer ACS: 34854 Regd. Office & Factory: Kolhupani, P.O. Chandanwari, Dehradun-248 007. Phone: 0135-2773429, 2772038, E-mail: ddn@shivalikrasayan.com Works Dahej-II: D-2/CH/41/A, GIDC Industrial Estates, Dahej-II, Pin- 392140 Distt, Bharuch (Gujarat) R&D Centre: SP-1192 A&B, Phase-IV, Industrial Area, Bhiwadi-301019, Dist. Alwar, Bhiwadi (Rajasthan) Tel.: 07240009670 Annexure-A A Shivalik Rasayan Ltd. Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun-248007 CIN: L24237UR1979PLC005041 E-mail : cs@shivalikrasayan.com,www.shivalikrasayan.com Un-audited Standalone and Consolidated Financial Results for the Quarter ended on 30th June 2026 PARTI All Figures in Rs. Lakhs Excepts Earninl! Per Shares Standalone Consolidated Three month period ended Year Ended Three month period ended Year Ended Particulars 30-06-2026 31-03-2026 30-06-2025 31-03-2026 30-06-2026 31-03-2026 30-06-2025 31-03-2026 Un-audited Un-audited Un-audited Audited Audited Un-audited Un-audited Audited 1 Income from operations (a) Net Sales/Income from operations 4,844.16 4,216.91 4,626.45 17,023.35 9,633.85 10,281.57 8,930.93 36,800.32 (b) Other Income 10.36 18.12 12.68 96.45 96.52 191.64 59.71 407.76 Total Revenue 4,854.52 4,235.03 4,639.13 17,119.80 9,730.37 10,473.21 8,990.64 37,208.09 2 Expenses a) Cost of Material Consumed 3,015.99 2,308.10 2,075.91 10,264.52 5,277.06 4,917.33 4,535.68 19,699.33 b) Purchase of Stock-in-Trade - - - - - - - - c) Changes in inventory ofFinished Goods and Work in -220.74 23.25 435.88 (1,604.28) (369.79) 633.66 247.39 (861.89) Progress d) Employees Benefits Expenses 588.14 624.41 591.54 2,586.16 1,519.52 1,564.32 1,400.57 6,055.47 e) Finance Cost 125.09 207.40 146.43 610.26 207.97 245.70 261.77 960.00 f) Depreciation and Amortisation Expenses 262.50 242.55 301.41 1,154.81 441.19 415.87 481.54 1,876.67 g) Other expenses 774.86 562.66 886.42 3,159.20 2,088.56 1,923.69 1,649.05 7,330.95 Total Expenses 4,545.84 3,968.37 4,437.59 16,170.67 9,164.52 9,700.58 8,576.00 35,060.52 3 Profit/(Loss) before Exceptional Items & Tax (1-2) 308.68 266.66 201.54 949.13 565.85 772.63 414.64 2,147.57 4 Exceptional Items (Commercial Tax Expenses Related to - - - - - - - Earlier Year) 5 Profit/(Loss) before Extra Ordinary Items & Tax (3-4) 308.68 266.66 201.54 949.13 565.85 772.63 414.64 2,147.57 6 Tax Expenses Current Year 100.10 (61.76) 52.92 202.27 183.10 3.52 109.88 457.10 MAT Credit Entitlement -46.16 108.35 (17.71) (36.44) (46.16) 108.35 (17.71) (36.43) Deferred Tax Liability -10.78 (52.55) 44.25 (33.95) (21.22) (56.56) 40.34 (69.98) Total Tax Expenses 43.16 (5.96) 79.46 131.88 115.72 55.31 132.50 350.69 7 Net Profit/Loss for the period (5-6) 265.52 272.62 122.08 817.25 450.13 717.32 282.13 1,796.88 8 Other Comprehensive Income Item that will not be reclassified to Profit & Loss - - - - - - - - Total Comprehensive income Net of Tax 265.52 272.62 122.08 817.25 450.13 717.32 282.13 1,796.88 9 Total Comprehensive income for the Period (7+8) 265.52 272.62 122.08 817.25 450.13 717.32 282.13 1,796.88 10 Net Profit/ (loss) attribulable to a) Controlling Interest 265.52 272.62 122.08 817.25 340.23 452.54 160.05 1,213.60 b) Non Controlling Interest - - - - 109.89 264.77 122.08 583.27 11 Paid-up equity share capital (Rs.5/-per share) 787.52 787.52 787.52 787.52 787.52 787.52 787.52 787.52 12 Earning Per Share (Rs.) (a) Basic 1.69 1.73 0.78 5.19 2.16 2.87 1.02 7.71 (b) Diluted 1.69 1.73 0.78 5.19 2.16 2.87 1.02 7.71 NOTES : I The Un-audited financial results for the quarter ended on 30.06.2026 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.08.2026. 2 The figures are regrouped in previous year also, wherever considered necessary. 3 The company operates in business segment viz Agro Chemical, Pharma AP! & Pharma Formulations. 4 The Earning Per Share has been calculated as per Ind AS-33. 5 Consolidated results of the company includes the results of its Associate i.e., Medicamen Biotech Limited. ~ 6 The figures of the quarter ended on 31.03.2026 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the financial year ended on 31.03.2026 _;" ,S behalf of Board of Directors aA~ hivalik Rasayan L-imited Nay., De/hi ,~ ~,:► " ~,-. ,/. , . o ·. : >',v, z::.-:( ;::::hnoi) , _ ,: ~ ..,, Chairman Pla [Showing first 8,000 characters — download PDF for full document]